{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:54:39Z","timestamp":1782863679006,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12185-025-04128-4","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:26:44Z","timestamp":1765805204000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-7517","authenticated-orcid":false,"given":"Keichiro","family":"Mihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Miyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"4128_CR1","unstructured":"Rieger L, Irlinger K, F\u00fcchsl F, Tietje M, Purcarea A, Barbian NM, et al. Bassermann F. Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens. Blood. 2025;blood.2024027616."},{"issue":"8","key":"4128_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"key":"4128_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"4128_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12185-024-03766-4","volume":"120","author":"T Ochi","year":"2024","unstructured":"Ochi T, Konishi T, Takenaka K. Bispecific antibodies for multiple myeloma: past, present and future. Int J Hematol. 2024;120:23\u201333.","journal-title":"Int J Hematol"},{"key":"4128_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180080","volume":"134","author":"L Zhou","year":"2024","unstructured":"Zhou L, Velegraki M, Wang Y, Mandula JK, Chang Y, Liu W, et al. Spatial and functional targeting of intratumoral Tregs reverses CD8+ T cell exhaustion and promotes cancer immunotherapy. J Clin Invest. 2024;134:e180080.","journal-title":"J Clin Invest"},{"key":"4128_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2023022499","volume":"143","author":"H Lee","year":"2024","unstructured":"Lee H, Neri P, Bahlis NJ. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood. 2024;143:1211\u20137.","journal-title":"Blood"},{"key":"4128_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:393\u2013407.","journal-title":"N Engl J Med"},{"key":"4128_CR8","doi-asserted-by":"crossref","unstructured":"Kim SH, Marshall RF, Wai KM, Rahimy E, Vingopoulos F, Mishra K, et al. ocular adverse events of antibody drug conjugates and association with survival from a real-world database. Cornea. 2025.","DOI":"10.1097\/ICO.0000000000003997"},{"key":"4128_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13045-021-01172-5","volume":"14","author":"K Marquant","year":"2021","unstructured":"Marquant K, Quinquenel A, Arndt C, Denoyer A. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol. 2021;14:159.","journal-title":"J Hematol Oncol"},{"key":"4128_CR10","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1182\/bloodadvances.2024013540","volume":"8","author":"NM Kalariya","year":"2024","unstructured":"Kalariya NM, Hildebrandt MAT, Hansen DK, Sidana S, Khouri J, Ferreri CJ, et al. Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience. Blood Adv. 2024;8:4679\u201388.","journal-title":"Blood Adv"},{"key":"4128_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","volume":"5","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ, Rasche L, Sidana S, Zweegman S, Garfall AL. T cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment. Blood Cancer Discov. 2024;5:388\u201399.","journal-title":"Blood Cancer Discov"},{"key":"4128_CR12","unstructured":"Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, et al. Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. Blood Adv. 2025:bloodadvances.2025017597."},{"key":"4128_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41408-025-01330-9","volume":"15","author":"MJ Steinhardt","year":"2025","unstructured":"Steinhardt MJ, Schaefers C, Leypoldt LB, Blau IW, Harzer M, Zhou X, et al. Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement. Blood Cancer J. 2025;15:126.","journal-title":"Blood Cancer J"},{"key":"4128_CR14","unstructured":"Rieger L, Irlinger K, F\u00fcchsl F, Tietje M, Purcarea A, Barbian NM, et al. Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens. Blood. 2025;blood.2024027616."},{"key":"4128_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s12185-021-03093-y","volume":"113","author":"K Nozaki","year":"2021","unstructured":"Nozaki K, Fujioka Y, Sugiyama D, Ishikawa J, Iida M, Shibata M, et al. Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance. Int J Hematol. 2021;113:772\u20134.","journal-title":"Int J Hematol"},{"key":"4128_CR16","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s43018-025-00982-7","volume":"6","author":"HC Hope","year":"2025","unstructured":"Hope HC, de Sostoa J, Ginefra P, Andreatta M, Chiang YH, Ronet C, et al. Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Nat Cancer. 2025;6:1524\u201336.","journal-title":"Nat Cancer"},{"key":"4128_CR17","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1182\/bloodadvances.2024015648","volume":"9","author":"B Mohan Lal","year":"2025","unstructured":"Mohan Lal B, Alzubi M, Alrawabdeh J, Shaughnessy JD Jr, Zhan F, Siegel ER, et al. Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma. Blood Adv. 2025;9:2155\u20138.","journal-title":"Blood Adv"},{"issue":"25","key":"4128_CR18","first-page":"00218","volume":"S2152\u20132650","author":"P Mewawalla","year":"2025","unstructured":"Mewawalla P, Dileo R, Yin Y, Strouse C, Shaikh H, Davis JA, et al. Real-world outcomes of sequential BCMA-directed therapies in relapsed refractory multiple myeloma after belantamab exposure. Clin Lymphoma Myeloma Leuk. 2025;S2152\u20132650(25):00218\u201326.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4128_CR19","doi-asserted-by":"crossref","unstructured":"Musa H, Mielnik M, Trudel S, Weisel K, Mockus-Daehn T, Ferron-Brady G, et al. Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma. Haematologica. 2025.","DOI":"10.3324\/haematol.2025.288203"},{"key":"4128_CR20","volume":"2","author":"M Hultcrantz","year":"2025","unstructured":"Hultcrantz M, Derkach A, Hassoun H, Korde N, Maclachlan K, Mailankody S, et al. Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: a real-world experience. Blood. 2025;2:100103.","journal-title":"Blood"},{"key":"4128_CR21","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2023012066","volume":"8","author":"KR Reyes","year":"2024","unstructured":"Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, et al. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv. 2024;8:2207\u201316.","journal-title":"Blood Adv"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04128-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04128-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04128-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:08:59Z","timestamp":1782860939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04128-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4128"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04128-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}